Growth Metrics

Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)

Boston Scientific recorded quarterly Current Deferred Revenue of $147.0 million in Q3 2020, up 2.8% quarter-over-quarter from $143.0 million in Q2 2020.

Boston Scientific's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $147.0 million for Q3 2020.

  • In Q3 2020, Current Deferred Revenue changed N/A year-over-year to $147.0 million; the TTM figure through Sep 2020 stood at $147.0 million (changed N/A YoY), while the FY2019 annual figure was $144.0 million, changed N/A from the prior year.
  • Current Deferred Revenue came in at $147.0 million for Q3 2020 at Boston Scientific, up from $143.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $251.0 million in Q1 2020 to a low of $143.0 million in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 147.00 Mn
Jun 30, 2020 143.00 Mn
Mar 31, 2020 251.00 Mn
Dec 31, 2019 144.00 Mn